A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 297-313

  Siragy, Helmy M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Aliskiren; Angiotensin II receptor blocker; Cancer; Myocardial infarction; Renin angiotensin system; Safety

Indexed keywords

ALISKIREN; AMIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE;

CHEMICALLY INDUCED DISORDER; HEART INFARCTION; HUMAN; HYPERTENSION; NEOPLASM; REVIEW;

AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; FUMARATES; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; NEOPLASMS;

EID: 80053311854     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S15541     Document Type: Review

References (77)

1. Fogari R, Zoppi A. New class of agents for treatment of hypertension: focus on direct renin inhibition. Vasc Health Risk Manag. 2010;6: 869-882.
2. Sever PS, Gradman AH, Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst. 2009;10(2):65-76.
3. Volpe M, Savoia C, De Paolis P, Ostrowska B, Tarasi D, Rubattu S. The reninangiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol. 2002;13(Suppl 3):S173-S178.
4. Gullapalli N, Bloch MJ, Basile J. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends. Ther Adv Cardiovasc Dis. 2010;4(6):359-373.
5. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6): 1206-1252.
6. Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens. 1993;11(Suppl 3):S49-S52.
7. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129(1 Suppl):169S-173S.
8. Sica DA, Black HR. Angioedema in heart failure: occurrence with ACE inhibitors and safety of angiotensin receptor blocker therapy. Congest Heart Fail. 2002;8(6):334-341, 345.
9. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J. 2001;22(15):1343-1352.
10. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 2001;92(9):2462-2470.
11. Verdecchia P, Angeli F, Repaci S, Mazzotta G, Gentile G, Reboldi G. Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag. 2009;5:939-948.
12. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114(8):838-854.
13. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensinreceptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627-636.
14. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ. 2004;329(7477):1248-1249.
15. Sanoski CA. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension. Pharmacotherapy. 2009;29(2):193-212.
16. White WB, Bresalier R, Kaplan AP, et al. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich). 2010;12(10):765-775.
17. Bezencon O, Bur D, Weller T, et al. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. J Med Chem. 2009; 52(12):3689-3702.
18. Tice CM, Xu Z, Yuan J, et al. Design and optimization of renin inhibitors: Orally bioavailable alkyl amines. Bioorg Med Chem Lett. 2009; 19(13):3541-3545.
19. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264(3):224-236.
20. Siragy HM. Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Adv Ther. 2010;27(5):257-284.
21. Zheng Z, Shi H, Jia J, Li D, Lin S. A systematic review and metaanalysis of aliskiren and angiotension receptor blockers in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst. 2010 Nov 8. [Epub ahead of print].
22. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433-2446.
23. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17-24.
24. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both, on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530-537.
25. Solomon SD, Hee SS, Shah A, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011. [Epub ahead of print].
26. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf. 1999;21(1):23-33.
27. Cozaar® (losartan potassium tablets) [prescribing information]. 2006. Merck and Co., Inc, Whitehouse Station, NJ.
28. Diovan® (valsartan) Tablets [prescribing information]. 2008. Novartis Pharmaceuticals Corporation, East Hanover, NJ.
29. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426):2022-2031.
30. McMurray J. Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate. BMJ. 2005; 330(7502):1269.
31. Opie LH. Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed. BMJ. 2005;330(7502):1270-1271.
32. Lewis EJ. Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes. BMJ. 2005;330(7502):1269-1270.
33. Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation. 2006;114(8): 855-860.
34. Yousef ZR, Leyva F, Gibbs C. Angiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credible. BMJ. 2005;330(7502):1270-1271.
35. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J. 2005;26(22):2381-2386.
36. McDonald MA, Simpson SH, Ezekowitz JA, Gyenes G, Tsuyuki RT. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ. 2005;331(7521):873.
37. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens. 2005;23(12): 2113-2118.
38. Cheung BM, Cheung GT, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens. 2006;20(1):37-43.
39. Messerli FH, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J. 2009;30(20): 2427-2430.
40. Walker E, Hernandez AV, Kattan MW. Meta-analysis: Its strengths and limitations. Cleve Clin J Med. 2008;75(6):431-439.
41. Suzuki H, Kanno Y. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res. 2005;28(4): 307-314.
42. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15): 1547-1559.
43. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174-1183.
44. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362(16):1477-1490.
45. Sawada T, Yamada H, Dahlöf B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J. 2009; 30(20):2461-2469.
46. Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbiditymortality study. Lancet. 2007;369(9571):1431-1439.
47. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359(23):2456-2467.
48. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12): 1225-1237.
49. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23): 1667-1675.
50. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36(6):1218-1226.
51. Goldstein MR, Mascitelli L, Pezzetta F. Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol. 2010;11(9):817-818.
52. Kanehira T, Tani T, Takagi T, Nakano Y, Howard EF, Tamura M. Angiotensin II type 2 receptor gene deficiency attenuates susceptibility to tobacco-specific nitrosamine-induced lung tumorigenesis: involvement of transforming growth factor-b-dependent cell growth attenuation. Cancer Res. 2005;65(17):7660-7665.
53. Clere N, Corre I, Faure S, et al. Def iciency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer. 2010;127(10): 2279-2291.
54. Meredith PA, McInnes GT. Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol. 2010;11(9):819.
55. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5): 875-886.
56. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011; 12(1):65-82.
57. The ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. J Hypertens. 2011;29(4):623-635.
58. Huang CC, Chan WL, Chen YC, et al. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol. 2011;107(7):1028-1033.
59. FDA Drug Safety Communication. Ongoing safety review of the angiotensin receptor blockers and cancer. 2010. Available at: http:// www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm218845.htm. Accessed March 2011.
60. Tekturna® (aliskiren) Tablets, Oral [prescribing information]. 2010. Novartis Pharmaceuticals Corporation, East Hanover, NJ.
61. Atacand® (candesartan cilexetil) Tablets [prescribing information]. 2009. AstraZeneca LP, Wilmington, DE.
62. Avapro® (irbesartan) Tablets [prescribing information]. 2007. Bristol Myers Squibb Sanofi-Synthelabo Partnership, New York, NY.
63. Micardis® (telmisartan) Tablets [prescribing information]. 2009. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
64. Teveten® (eprosartan mesylate) Tablets [prescribing information]. 2007. Abbott Laboratories, North Chicago, IL.
65. Benicar® (olmesartan medoxomil) Tablets [prescribing information]. 2009. Daiichi Sankyo, Inc., Parsippany, NJ.
66. Solomon SD, Wang D, Finn P, et al. Effect of candesartan on causespecific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004;110(15):2180-2183.
67. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759-766.
68. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-771.
69. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-776.
70. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-781.
71. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20): 1893-1906.
72. McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol. 2006;47(4):726-733.
73. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
74. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002; 360(9335):752-760.
75. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138(7):542-549.
76. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
77. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582-1587.